327 related articles for article (PubMed ID: 29504634)
1. Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: A prospective follow-up study.
Jairam R; Drossaerts J; Vrijens D; Leue C; van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2018 Jun; 37(5):1801-1808. PubMed ID: 29504634
[TBL] [Abstract][Full Text] [Related]
2. Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation.
Drossaerts J; Vrijens D; Leue C; Schilders I; Van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2016 Nov; 35(8):1011-1016. PubMed ID: 26351817
[TBL] [Abstract][Full Text] [Related]
3. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
Marinkovic SP; Ford JC
BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
[TBL] [Abstract][Full Text] [Related]
4. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
[TBL] [Abstract][Full Text] [Related]
5. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
6. Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study.
Lee KS; Yoo TK; Liao L; Wang J; Chuang YC; Liu SP; Chu R; Sumarsono B
BMC Urol; 2017 Nov; 17(1):108. PubMed ID: 29162085
[TBL] [Abstract][Full Text] [Related]
7. Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
Chartier-Kastler E; Le Normand L; Ruffion A; Dargent F; Braguet R; Saussine C; Tanneau Y; Graziana JP; Ragni E; Rabut B; Rousseau T; Biardeau X; Gamé X; Pierrevelcin J; Brassart E; Fourmarier M; Stoica G; Berrogain N; Yaghi N; Pecoux F; Capon G; Ferchaud J; Peyrat L; Bryckaert PE; Karsenty G; Melotti A; Abouihia A; Keller DUJ; Cornu JN
Eur Urol Focus; 2021 Nov; 7(6):1430-1437. PubMed ID: 32907782
[TBL] [Abstract][Full Text] [Related]
8. Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment.
Marcelissen TA; Leong RK; Nieman FH; van Lankveld JJ; van Kerrebroeck PE; de Wachter SG
BJU Int; 2011 Dec; 108(11):1834-8. PubMed ID: 21810157
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
[TBL] [Abstract][Full Text] [Related]
10. The Value of Ambulatory Urodynamics in the Evaluation of Treatment Effect of Sacral Neuromodulation.
Drossaerts J; Rademakers KLJ; Rahnama'i SM; Marcelissen T; Van Kerrebroeck P; van Koeveringe G
Urol Int; 2019; 102(3):299-305. PubMed ID: 30612126
[TBL] [Abstract][Full Text] [Related]
11. Onset of Action of Sacral Neuromodulation in Lower Urinary Tract Dysfunction-What is the Optimal Duration of Test Stimulation?
Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; van Kerrebroeck P
J Urol; 2018 Jun; 199(6):1584-1590. PubMed ID: 29291416
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
13. Sacral neuromodulation treatment for urinary voiding dysfunctions: results of treatment with the largest single-center series in a tertiary referral center in Turkey.
Kütükoğlu MU; Altuntaş T; Şahin B; Onur AR
Turk J Med Sci; 2023 Feb; 53(1):206-210. PubMed ID: 36945940
[TBL] [Abstract][Full Text] [Related]
14. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
[TBL] [Abstract][Full Text] [Related]
15. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
[TBL] [Abstract][Full Text] [Related]
16. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
[TBL] [Abstract][Full Text] [Related]
17. Optimal Lead Positioning in Sacral Neuromodulation: Which Factors Are Related to Treatment Outcome?
Jairam R; Marcelissen T; van Koeveringe G; van Kerrebroeck P
Neuromodulation; 2017 Dec; 20(8):830-835. PubMed ID: 28877395
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
[TBL] [Abstract][Full Text] [Related]
19. Detailed Investigation of Bladder Diary Parameters During Sacral Neuromodulation in Patients With Overactive Symptoms.
Van de Borne S; Tilborghs S; Vaganée D; Vermandel A; De Wachter S
Neuromodulation; 2023 Dec; 26(8):1831-1835. PubMed ID: 36266179
[TBL] [Abstract][Full Text] [Related]
20. An overview of sacral neuromodulation: a treatment for patients with symptoms of lower urinary tract dysfunction.
Fletcher N
Br J Nurs; 2020 Aug; 29(15):848-856. PubMed ID: 32790556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
